Crestline Management’s Zimmer Biomet ZBH Stock Holding History

Crestline Management’s Portfolio ZBH Stock Details ZBH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-19,406	Closed	-$2.76M	–	278
2021 Q3	$2.76M	Buy	+19,406	New	+$2.85M	0.26%	84
2017 Q3	–	Sell	-5,562	Closed	-$693K	–	175
2017 Q2	$693K	Sell	5,562 -5,444	-49%	-$645K	0.09%	103
2017 Q1	$1.3M	Sell	11,006 -11,028	-50%	-$1.25M	0.24%	44
2016 Q4	$2.21M	Buy	22,034 +7,320	+50%	+$785K	0.55%	4
2016 Q3	$1.86M	Buy	+14,714	New	+$1.82M	0.24%	47

Other funds holding ZBH

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Crestline Management's ZBH Position: Q4 2021 in Review

Crestline Management sold out of Zimmer Biomet (ZBH) in Q4 2021, closing a stake of 19,406 shares — an estimated $2.76M sold.

Crestline Management first reported a position in ZBH in Q3 2016 and held it in 5 quarters. The position peaked at $2.76M in Q3 2021. 998 funds tracked by Wall St. Rank hold ZBH as of Q4 2021.

Crestline Management reported no remaining Zimmer Biomet position as of Q4 2021 after selling out during the quarter.
Crestline Management sold 19,406 Zimmer Biomet shares in Q4 2021, an estimated $2.76M.
Crestline Management first reported a position in Zimmer Biomet in Q3 2016 and held it in 5 quarters.
Crestline Management's Zimmer Biomet position peaked at $2.76M in Q3 2021.
998 funds tracked by Wall St. Rank held Zimmer Biomet as of Q4 2021.

Based on Crestline Management's 13F filing for Q4 2021, filed 14 Feb 2022.